STOCK TITAN

Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Savara Inc. to present at H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023
Positive
  • None.
Negative
  • None.

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023 at 3:30pm ET/12:30pm PT. A live webcast of the presentation will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

Savara Inc. IR & PR

Anne Erickson

anne.erickson@savarapharma.com

(512) 851-1366

Source: Savara Inc.

Savara Inc.

NASDAQ:SVRA

SVRA Rankings

SVRA Latest News

SVRA Stock Data

578.36M
155.48M
4.58%
96.62%
8%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
AUSTIN